OOIR: Observatory of International Research

Papers

(The TQCC of Melanoma Research is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-08-01 to 2025-08-01.)

Article	Citations
Clinical features, molecular characteristics and surgical management of primary penile mucosal melanoma based on the European Association of Urology Penile Cancer Guidelines	26
Clinicopathological demographics of malignant melanomas of the vulva and vagina in Japan	19
Analysis of circulating tumor DNA during checkpoint inhibition in metastatic melanoma using a tumor-agnostic panel	18
Genetic concordance in melanoma: insights from primary tumors and their matched distant metastases	18
Real-world evidence on efficacy and toxicity of targeted therapy in older melanoma patients treated in a tertiary-hospital setting	17
Dacarbazine in the management of metastatic melanoma in the era of immune checkpoint therapy: a valid option or obsolete?	17
Lack of association between anatomical sites of scalp melanomas and brain metastases does not support direct vascular spread	16
Rare immune-related adverse events in a patient with metastatic melanoma: a case report highlighting sarcoidosis-like reactions triggered by immune-checkpoint inhibitors	15
Do cortisol and psychological distress levels impact the effectiveness of immunotherapy in patients with metastasized melanoma? A pilot study	13
Immune-related adverse events are associated with therapeutic efficacy of immunotherapy in patients with melanoma brain metastases	13
Brain metastases during follow-up of patients with resected cutaneous melanoma	12
The potential of using artificial intelligence to improve skin cancer diagnoses in Hawai‘i’s multiethnic population	12
Study of clinical characteristics and risk factors for amelanotic/hypomelanotic melanoma in an Australian cohort	12
Comprehensive clinical imaging, histopathological analysis and liquid biopsy-based surveillance of human uveal melanoma in a prolonged rabbit xenograft model	12
Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis: Erratum	10
Assessment of lipid and pigment content in suspicious melanocytic lesions to improve melanoma detection	10
Pretreatment CD8+PD-1+ to CD4+PD-1+ ratio is associated with the prognosis of advanced melanoma patients treated with PD-1 inhibitors	10
Exploring the clinical significance of specific immune-related adverse events in melanoma patients undergoing immune checkpoint inhibitor therapy	10
Immunotherapy-induced granulomatous reaction in patients with melanoma	10
Diffuse large B-cell lymphoma mimicking metastatic melanoma: the importance of biopsies in the era of immune checkpoint inhibitors	10
Cytomegalovirus gastritis as a rare adverse event during combined ipilimumab and nivolumab in a patient with melanoma	9
Challenging pigmented lesions in melanoma patients during checkpoint-inhibitors therapy	9
Machine learning developed an intratumor heterogeneity signature for predicting prognosis and immunotherapy benefits in skin cutaneous melanoma	9
Clinical and dermoscopical presentation of nivolumab-induced pemphigoid in a metastatic melanoma patient	9
Electrical impedance spectroscopy significantly enhances correct biopsy choice for pigmented skin lesions beyond clinical evaluation and dermoscopy	9

Association of baseline neutrophil-to-lymphocyte ratio and prognosis in melanoma patients treated with PD-1/PD-L1 blockade: a systematic review and meta-analysis	8
Programmed death ligand-1 PET imaging in patients with melanoma: a pilot study	8
Updated meta-analysis on the risk of melanoma associated with phosphodiesterase type 5 inhibitors	8
Relationships between survival and real-world recurrence-free survival or distant metastasis-free survival among patients with completely resected stage IIB or IIC melanoma	8
GLI-1 polymorphisms of Hedgehog pathway as novel risk and prognostic biomarkers in melanoma patients	8
Regular use of vitamin D supplement is associated with fewer melanoma cases compared to non-use: a cross-sectional study in 498 adult subjects at risk of skin cancers	8
Diagnostic and prognostic value of Beclin 1 expression in melanoma: a meta-analysis	8
Ultraviolet A radiation exposure and melanoma: a review	8
Postimmunotherapy antiglial fibrillary acidic protein encephalomyelitis after adjuvant pembrolizumab for melanoma	8
Immunotherapy for treatment of female genital tract melanoma: National Cancer Database analysis	8
Evaluation of surgical modalities for stage 0 to stage II acral lentiginous melanoma: a National Cancer Database study	7
LINC01063 functions as an oncogene in melanoma through regulation of miR-5194-mediated SOX12 expression	7
Neurologic adverse events associated with BRAF and MEK inhibitor therapy in patients with malignant melanoma: a disproportionality analysis using the Food and Drug Administration Adverse Event Reporti	7
Drug reactions with eosinophilia and systemic symptoms induced by immune checkpoint inhibitors: an international cohort of 13 cases	7
Uncomplicated pregnancy and delivery under ongoing nivolumab therapy for metastatic melanoma	7
Interfering with aggregated α-synuclein in advanced melanoma leads to a major upregulation of MHC class II proteins	7
Temporal correlation between the first melanoma and the first noncutaneous tumor in CKDN2A genotyped patients	7
Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series	6
Hemophagocytic lymphohistiocytosis induced by dabrafenib-trametinib in a patient with metastatic melanoma: a case report and pharmacovigilance analysis	6
Exacerbation of Kaposi sarcoma following BRAF/MEK inhibitor therapy in a melanoma patient: a case report and mechanistic insight	6
Intratumoural and systemic inflammation as predictors for treatment response in BRAF-mutated melanoma patients under targeted therapies	6
Documenting the histologic response of metastatic melanoma to combination therapy with BRAF and MEK inhibitors	6
Clostridium difficile infection and immune checkpoint inhibitor–induced colitis in melanoma: 18 cases and a review of the literature	6
Knockdown of enhancer of rudimentary homolog expression attenuates proliferation, cell cycle and apoptosis of melanoma cells	6
Pembrolizumab-induced plaque psoriasis successfully treated with risankizumab in a patient with stage IV cutaneous melanoma	6
The effect of microRNA-9 overexpression on inhibition of melanoma cancer stem cells tumorigenicity	6
Exceptional response to combination ipilimumab and nivolumab in metastatic uveal melanoma: Insights from genomic analysis	6
Variance from published guidelines and changes in temporal trends in the management of cutaneous malignant melanoma: a 5-year update	6
Efficacy and safety of angiogenesis inhibitors in melanoma: a meta-analysis of seven randomized controlled trials	6
Temozolomide monotherapy versus combination therapies in melanoma: a meta-analysis of efficacy and safety	5
Bone marrow metastases: a systematic review of a neglected involvement in malignant melanoma	5
Pseudoprogression in a patient with metastatic melanoma treated with PD-1 and LAG-3 inhibition	5
Resolution of diffuse cuticular melanosis under immunotherapy in a patient with metastatic melanoma	5
Sensitivity of treatment-free survival to subgroup analyses in patients with advanced melanoma treated with immune checkpoint inhibitors	5
Long-term clinical evidence of comparable efficacy and toxicity of nivolumab and pembrolizumab in advanced melanoma treatment	5
Screening costs associated with donor selection for fecal microbiota transplantation for treatment of PD-1 refractory melanoma patients	5
Simultaneous melanomas in the setting of multiple primary melanomas	5
Successful use of rituximab for refractory hemophagocytic lymphohistiocytosis in a melanoma patient treated with targeted therapy	4
A retrospective study of clinicopathological and prognostic characteristics in 177 Chinese patients with acral melanoma: heterogeneity based on tumor site	4
Ultra-high-frequency ultrasound monitoring of melanomas arising in congenital melanocytic nevi: a case series	4
The human and animals’ malignant melanoma: comparative tumor models and the role of microbiome in dogs and humans	4
Intracranial hemorrhage caused by dabrafenib and trametinib therapy for metastatic melanoma	4
Melanoma in the head and neck region: the value of preoperative imaging in melanoma stage I–II	4
The immunologic balance: three cases of rituximab-associated melanoma	4
Chemosaturation with percutaneous hepatic perfusion of melphalan for metastatic uveal melanoma	4
Patterns of radiological response to tebentafusp in patients with metastatic uveal melanoma	4
Assessing melanoma prognosis: the interplay between patient profiles, survival, and BRAF, NRAS, KIT, and TWT mutations in a retrospective multi-study analysis	4
Molecular profiling of primary uveal melanoma: results of a Polish cohort	4
Impact of systemic imaging surveillance on survival from metastatic uveal melanoma	4
Identification of heterogeneity and prognostic key genes associated with uveal melanoma using single-cell RNA-sequencing technology	4

Real-world outcomes of different lines and sequences of treatment in BRAF-positive advanced melanoma patients	4
Case report: response to the ERK1/2 inhibitor ulixertinib in BRAF D594G cutaneous melanoma	4
Management of heterogeneous tumor response patterns to immunotherapy in patients with metastatic melanoma	4
Reflectance confocal microscopy versus dermoscopy for the diagnosis of cutaneous melanoma: a head-to-head comparative meta-analysis	4
Melanoma risk during immunomodulating treatment	4
DNA methylation of GITR, OX40, 4-1BB, CD27, and CD40 correlates with BAP1 aberrancy and prognosis in uveal melanoma	4
Acute appendicitis secondary to desmoplastic melanoma metastasis in immune-checkpoint inhibitors era	4
COVID-19 vaccination mimicking lymph-node progression in a patient with melanoma: a case report	4
Melanoma and pregnant women: a systematic review and meta-analysis	4